Cargando…

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)

BACKGROUND: Morning symptoms associated with COPD have a negative impact on patients’ quality of life. Long-acting bronchodilators with rapid onset may relieve patients’ symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin, Jose M, Beeh, Kai M, Clemens, Andreas, Castellani, Walter, Schaper, Lennart, Saralaya, Dinesh, Gunstone, Anthony, Casamor, Ricard, Kostikas, Konstantinos, Aalamian-Mattheis, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934556/
https://www.ncbi.nlm.nih.gov/pubmed/27418815
http://dx.doi.org/10.2147/COPD.S106127
_version_ 1782441356823625728
author Marin, Jose M
Beeh, Kai M
Clemens, Andreas
Castellani, Walter
Schaper, Lennart
Saralaya, Dinesh
Gunstone, Anthony
Casamor, Ricard
Kostikas, Konstantinos
Aalamian-Mattheis, Maryam
author_facet Marin, Jose M
Beeh, Kai M
Clemens, Andreas
Castellani, Walter
Schaper, Lennart
Saralaya, Dinesh
Gunstone, Anthony
Casamor, Ricard
Kostikas, Konstantinos
Aalamian-Mattheis, Maryam
author_sort Marin, Jose M
collection PubMed
description BACKGROUND: Morning symptoms associated with COPD have a negative impact on patients’ quality of life. Long-acting bronchodilators with rapid onset may relieve patients’ symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator profile of glycopyrronium (GLY) and tiotropium (TIO) during the first few hours after dosing in patients with moderate-to-severe COPD. METHODS: Patients were randomized (1:1) to receive either once-daily GLY (50 μg) or TIO (18 μg) and corresponding placebos in a cross-over design for 28 days. The primary objective was to demonstrate the superiority of GLY versus TIO in area under the curve from 0 to 4 hours (AUC(0-4h)) forced expiratory volume in 1 second (FEV(1)) after the first dose. The secondary objective was to compare GLY versus TIO using the patient reported outcomes Morning COPD Symptoms Questionnaire 3 hours post-inhalation. RESULTS: One-hundred and twenty-six patients were randomized (male 70.2%; mean age 65.7 years) and 108 patients completed the study. On Day 1, GLY resulted in significantly higher FEV(1) AUC(0-4h) after the first dose versus TIO (treatment difference [Δ], 0.030 L, 95% confidence interval 0.004–0.056, P=0.025). Improvements in morning COPD symptoms from baseline at Days 1 and 28 were similar between GLY and TIO. Post hoc analysis of the FEV(1) AUC(0-4h) by time point on Day 1 showed significant improvements in patients receiving GLY versus TIO at 5 minutes (Δ=0.029 L, P=0.015), 15 minutes (Δ=0.033 L, P=0.026), and 1 hour (Δ=0.044 L, P=0.014). Safety results were comparable between both treatments. CONCLUSION: The SPRING study demonstrates the superiority of GLY versus TIO in terms of superior bronchodilation in the first 4 hours after administration, thus extending the clinical data that support a faster onset of action of GLY versus TIO.
format Online
Article
Text
id pubmed-4934556
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49345562016-07-14 Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING) Marin, Jose M Beeh, Kai M Clemens, Andreas Castellani, Walter Schaper, Lennart Saralaya, Dinesh Gunstone, Anthony Casamor, Ricard Kostikas, Konstantinos Aalamian-Mattheis, Maryam Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Morning symptoms associated with COPD have a negative impact on patients’ quality of life. Long-acting bronchodilators with rapid onset may relieve patients’ symptoms. In the Symptoms and Pulmonary function in the moRnING study, we prospectively compared the rapid onset bronchodilator profile of glycopyrronium (GLY) and tiotropium (TIO) during the first few hours after dosing in patients with moderate-to-severe COPD. METHODS: Patients were randomized (1:1) to receive either once-daily GLY (50 μg) or TIO (18 μg) and corresponding placebos in a cross-over design for 28 days. The primary objective was to demonstrate the superiority of GLY versus TIO in area under the curve from 0 to 4 hours (AUC(0-4h)) forced expiratory volume in 1 second (FEV(1)) after the first dose. The secondary objective was to compare GLY versus TIO using the patient reported outcomes Morning COPD Symptoms Questionnaire 3 hours post-inhalation. RESULTS: One-hundred and twenty-six patients were randomized (male 70.2%; mean age 65.7 years) and 108 patients completed the study. On Day 1, GLY resulted in significantly higher FEV(1) AUC(0-4h) after the first dose versus TIO (treatment difference [Δ], 0.030 L, 95% confidence interval 0.004–0.056, P=0.025). Improvements in morning COPD symptoms from baseline at Days 1 and 28 were similar between GLY and TIO. Post hoc analysis of the FEV(1) AUC(0-4h) by time point on Day 1 showed significant improvements in patients receiving GLY versus TIO at 5 minutes (Δ=0.029 L, P=0.015), 15 minutes (Δ=0.033 L, P=0.026), and 1 hour (Δ=0.044 L, P=0.014). Safety results were comparable between both treatments. CONCLUSION: The SPRING study demonstrates the superiority of GLY versus TIO in terms of superior bronchodilation in the first 4 hours after administration, thus extending the clinical data that support a faster onset of action of GLY versus TIO. Dove Medical Press 2016-06-28 /pmc/articles/PMC4934556/ /pubmed/27418815 http://dx.doi.org/10.2147/COPD.S106127 Text en © 2016 Marin et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Marin, Jose M
Beeh, Kai M
Clemens, Andreas
Castellani, Walter
Schaper, Lennart
Saralaya, Dinesh
Gunstone, Anthony
Casamor, Ricard
Kostikas, Konstantinos
Aalamian-Mattheis, Maryam
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
title Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
title_full Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
title_fullStr Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
title_full_unstemmed Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
title_short Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
title_sort early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe copd patients: a cross-over blinded randomized study (symptoms and pulmonary function in the morning)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934556/
https://www.ncbi.nlm.nih.gov/pubmed/27418815
http://dx.doi.org/10.2147/COPD.S106127
work_keys_str_mv AT marinjosem earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT beehkaim earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT clemensandreas earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT castellaniwalter earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT schaperlennart earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT saralayadinesh earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT gunstoneanthony earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT casamorricard earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT kostikaskonstantinos earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning
AT aalamianmattheismaryam earlybronchodilatoractionofglycopyrroniumversustiotropiuminmoderatetoseverecopdpatientsacrossoverblindedrandomizedstudysymptomsandpulmonaryfunctioninthemorning